Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
IN

NASDAQ · INTS

Intensity Therapeutics, Inc.

Healthcare · Biotechnology

$3.50

Up+$0.12 (+3.55%)

Updated Nov 5, 2026, 4:08 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.29M
P/E ratio
-2.2
Dividend yield
0.00%
52-week range
$3.00 – $7.96
Volume
6.74K
Avg. volume
30.71M

Price performance · INTS

INTS price history

1M range · 0 trading sessions · Daily adjusted prices

INTS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest INTS news

The latest Smart Investors Daily articles mentioning INTS.

Stock researchCompany · Overview

INTS research

Overview

Company profile and research snapshot.

Company profile

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
INTS recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Aug 20, 2025BenchmarkSpeculative Buy—
Aug 12, 2025Brookline CapitalBuy—
Jan 13, 2025Alliance Global PartnersBuy—
Nov 21, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announced data for the first seven patients in Cohort A in the INVINCIBLE-4 Study will be presented in an ePoster by The Swiss Cancer Institute, the Comp

Yahoo · Sep 8, 2026

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By